Tetrous, Inc.

LOS ANGELES, Oct. 15, 2024 /PRNewswire/ -- Tetrous, Inc., a Sherman Oaks start up focused on bone-to-tendon healing following orthopedic surgery, announced today that a fourth patent (U.S. Patent Number 12,115,279) specifically related to the EnFix family of demineralized cortical bone fiber implants and their method of manufacture has been issued by the United States Patent and Trademark Office. Continue Reading Our growing intellectual property portfolio provides Tetrous a sustainable competitive advantage in enthesis repair. Post this EnFix TAC-O The EnFix family of allograft products are designed to enhance healing at the tendon to bone interface, i.e., at the enthesis, where failure often occurs. The 100% demineralized bone fiber (DBF) implants provide osteoinductivity and osteoconductivity, while FormLok™ technology imparts shape retention to the device, even in the wet environment of arthroscopic surgery. Optimal biologic performance is provided in an implant that has minimal disruption to the current surgical technique. The newly issued patent, titled "Demineralized Bone Fiber Implant Compositions and Methods for Rotator Cuff and ACL Repair", further augments Tetrous' strong portfolio of intellectual property covering demineralized cortical bone fiber implants, bone healing, and enhancement of tendon to bone repair. "We are pleased that the U.S. Patent Office has yet again recognized the uniqueness of our technology and has granted this additional patent.", said Andy Carter, PhD, Tetrous' Co-Founder, Director and co-inventor on the issued patent. "Our growing intellectual property portfolio provides Tetrous a sustainable competitive advantage in the enthesis repair market". More than 700 EnFix RC™ and EnFix TAC™ implants have been implanted in the US and Australia since July 1, 2023. Follow up MRIs on patients at six months post-surgery are consistently showing reformation of the enthesis, thickening of the tendon and little to no edema. While the majority of the procedures have been for rotator cuff, we are expanding the technology to additional applications in hip, biceps, achilles and ACL procedures. About Tetrous, Inc. Founded in 2019, Tetrous, Inc. utilizes next generation advanced technologies for enthesis repair in sports medicine applications. The first offerings in the EnFix family of products are EnFix RC and EnFix TAC for rotator cuff repair. Tetrous was conceived from technology developed for spine surgery. The Company is employing and expanding the technology for novel applications in sports medicine. Its core technology has been used in over 150,000 implants in spine applications. Tetrous enjoys significant IP protection for its EnFix family of products with multiple issued patents and, additionally, has an exclusive license to the demineralized bone fiber technology used in its products for sports medicine applications from TheraCell, an ISTO Biologics Company. EnFix®, EnFix RC™ and EnFix TAC™ are trademarks of Tetrous, Inc. FormLok™ is a trademark of TheraCell, Inc., an Isto Biologics company. For more information visit and follow us on LinkedIn (). SOURCE Tetrous WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

LOS ANGELES, May 8, 2024 /PRNewswire/ -- TETROUS, INC., a leading regenerative medicine company today announced that it has completed the first surgical cases using EnFix TAC™, its latest product that expands its line of EnFix™ implants to cover every surgical technique for rotator cuff repair. "When it comes to surgical outcomes in rotator cuff repair, enthesis healing is one of the most critical factors." The EnFix product line is specifically designed to address Enthesis Failure Syndrome. The EnFix technology utilizes proprietary demineralized cortical bone fibers to yield an osteoinductive and osteoconductive implant that promotes optimal biologic healing at the bone-to-tendon interface, resulting in reformation of the enthesis. With strong pre-clinical data and promising early clinical results showing healing at the bone-to-tendon interface, there is growing evidence supporting the applicability of the EnFix technology to address the unmet need for technology that can improve on the weak repair at the enthesis that is driving the high surgical failure rates in rotator cuff repairs. The EnFix TAC is the second offering in the EnFix family of implants and is available in two configurations, TAC-O and TAC-T, to accommodate the varied availability of bony real estate based on the size of the rotator cuff tear. While the EnFix RC™ is designed to be used with suture anchors, the EnFix TAC options are specifically designed to deliver the same enthesis healing properties in a graft that is intended for use independent of a suture anchor or with all-suture anchors. Nikhil Verma, MD, Professor and Director, Sports Medicine and Shoulder, Midwest Orthopedics at Rush, Head Team Physician, Chicago White Sox, who performed the first surgeries with the EnFix TAC said, "When it comes to surgical outcomes in rotator cuff repair, enthesis healing is one of the most critical factors. The EnFix implants address this crucial need with minimal disruption to the surgical procedure". He continued, "I believe these products will have a transformative impact on surgical protocols in rotator cuff repair". Since June 2023, in the initial commercial release of the EnFix implants, more than 400 grafts have been implanted in over 200 surgical cases in the US and Australia. "For me, the EnFix implants are a great solution as they add very little time to the case and are technically much easier to apply than other iterations of demineralized bone I have tried," said Ferdinand Liotta, MD, Orthopedic surgeon at ValleyOrtho, Glenwood Springs, CO, the second surgeon in the USA to use the EnFix TAC. "The results from our experience with the EnFix products are very promising. I believe that the addition of this technology will help patients heal and decrease the risk of failure or re-tear." About Tetrous, Inc. Founded in 2019, Tetrous, Inc. utilizes next generation advanced technologies for enthesis repair in sports medicine applications. The first offerings in the EnFix family of products are EnFix RC and EnFix TAC for rotator cuff repair. Tetrous was conceived from technology developed for spine surgery. The Company is employing and expanding the technology for novel applications in sports medicine. Its core technology has been used in over 100,000 implants in spine applications. The demineralized bone fiber technology used in Tetrous products is licensed exclusively for use in sports medicine from TheraCell, an ISTO Biologics Company. EnFix™, EnFix RC™ and EnFix TAC™ are trademarks of Tetrous, Inc. For more information visit and follow us on LinkedIn ( ). View original content to download multimedia: SOURCE Tetrous

LOS ANGELES, Feb. 13, 2024 /PRNewswire/ -- TETROUS, INC. unveils the addition of EnFix TAC to its family of EnFix™ demineralized bone allograft implants for use in rotator cuff surgery. The new implants will be showcased this week at the American Academy of Orthopaedic Surgeons (AAOS) annual conference in San Francisco, CA. Our technology is focused on healing the bone-to-tendon interface known as the enthesis. A regenerative medicine company guided by a team of influential surgeons, regenerative medicine scientists, and business leaders with experience in the orthopaedic space, Tetrous is focused on the unmet need in bone-to-tendon healing following orthopaedic surgery. Numerous clinical and preclinical studies show that the enthesis does not re-form following surgery, but instead results in the formation of scar tissue. Scar tissue does not allow proper transmission of tensile load from soft tissue to bone and is prone to fail. "With strong pre-clinical data and promising early clinical results showing healing at the bone-to-tendon interface following surgery using our EnFix RC demineralized bone fiber implant, we are excited to add EnFix TAC to our product line," stated John Bojanowski, Tetrous' Chief Commercialization Officer. "EnFix TAC is specifically designed to deliver the same enthesis healing properties while offering the flexibility to be used independently of the surgeon's suture anchor choice, readily accommodating surgeons who are moving to all-suture anchors." "The EnFix TAC comes in two shapes to provide optimal coverage of the bony real estate available based on the size of the rotator cuff tear," stated Andy Carter, Ph.D., Co-Founder and CTO. "Our technology is focused on healing the bone-to-tendon interface known as the enthesis. Clinical literature shows healing does not occur on its own. Whilst our initial products focus on the rotator cuff, we are also working on additional applications for ACL and achilles repair as product line extensions in the EnFix family. We were pleased to have two US patents granted in 2023 covering the EnFix devices and we continue to grow our patent portfolio." Tetrous products are currently being distributed in the United States and Australia, manufactured by established local tissue banks that have extensive experience with the technology. About Tetrous, Inc. Founded in 2019, Tetrous, Inc. utilizes next generation advanced technologies for enthesis repair in sports medicine applications. The first offerings in the EnFix family of products are EnFix RC and EnFix TAC for rotator cuff repair. Tetrous was conceived from technology developed for spine surgery. The Company is employing and expanding the technology for novel applications in sports medicine. Its core technology has been used in nearly 150,000 surgeries in spine applications. The demineralized bone fiber technology used in Tetrous products is licensed exclusively for use in sports medicine from TheraCell, an ISTO Biologics Company. EnFix™, EnFix RC™ and EnFix TAC™ are trademarks of Tetrous, Inc. For more information visit and follow us on LinkedIn ( ). View original content to download multimedia: SOURCE Tetrous